Brief: Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
05/01/2022 13:03
Jan 5 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY PHARMACEUTICALS OUTLINES EGANELISIB CLINICAL
DEVELOPMENT STRATEGY AND PROVIDES 2022 GUIDANCE
* INFINITY PHARMACEUTICALS - MARIO-4 REGISTRATION STUDY IN
FRONTLINE METASTATIC TRIPLE NEGATIVE BREAST CANCER TO BE
INITIATED BY YEAR END 2022
* INFINITY PHARMACEUTICALS - MARIO-P PLATFORM STUDY IN
MULTIPLE
SOLID TUMORS TO BE INITIATED ON A ROLLING BASIS IN 3Q 2022
* INFINITY PHARMACEUTICALS INC - EXPECTS TO END 2022 WITH
BETWEEN
$25 MILLION TO $35 MILLION IN CASH AND INVESTMENTS BASED ON ITS
CURRENT OPERATING PLANS
* INFINITY PHARMACEUTICALS INC - EXPECTS NET LOSS FOR 2022
TO
RANGE BETWEEN $45 MILLION TO $55 MILLION
Source text for Eikon: ID:nBwbpbJxpa
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX